Treatment is complex for patients with head and neck (H&N) cancers with specific site of
disease, stage, and pathologic findings guiding treatment decision-making. Treatment planning …

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity
(including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, …

The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment recommendations
for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck
Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Head and Neck Cancers focuses on glottic laryngeal cancer, which is the most common …

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for
Head and Neck (H&N) Cancers. These Insights describe the different types of particle …

PURPOSE The aim of the current work is to provide evidence-based recommendations to
practicing physicians and others on the management of the neck in patients with squamous …

Purpose: This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic
squamous cell carcinomas of the head and neck (HN), and salivary gland cancer (SGC). …

Although KIF5B–RET is the most common RET fusion in NSCLCs, RET inhibition with RXDX-105
resulted in responses only in non– KIF5B–RET -containing cancers. Novel approaches …

Purpose: The WEE1 tyrosine kinase regulates G 2 –M transition and maintains genomic
stability, particularly in p53-deficient tumors which require DNA repair after genotoxic therapy. …